Table 5. Distribution of the HLA -DRB1/DQB1 haplotypes in patients with type 1 diabetes mellitus and normal controls before and after correction for population stratification.
| Haplotypes | T1D n(%) | Controls n(%) | OR | CI 95% | p no-structured | p strutured |
|---|---|---|---|---|---|---|
| 01–0501 | 114 (8.3%) | 142 (10.2%) | 0.79 | (0.61–1.03) | 0.0819 | 0.068 |
| 0301–0201 | 389 (28.4%) | 109 (7.9%) | 4.64 | (3.69–5.83) | <0.0001 | <0.001 |
| 0301–0202 | 7 (0.5%) | 4 (0.3%) | 1.77 | (0.52–6.07) | 0.3546 | — |
| 0302–0402 | 0 (0.0%) | 17 (1.2%) | 0.29 | (0.00–0.048) | <0.0001 | <0.001 |
| 0401–0301 | 18 (1.3%) | 7 (0.5%) | 2.62 | (1.09–6.29) | 0.0251 | 0.107 |
| 0401–0302 | 105 (7.7%) | 40 (2.9%) | 2.79 | (1.92–4.05) | <0.0001 | <0.001 |
| 0402–0301 | 11 (0.8%) | 2 (0.1%) | 5.6 | (1.24–25.32) | 0.0116 | 0.008 |
| 0402–0302 | 87 (6.3%) | 23 (1.7%) | 4.02 | (2.52–6.40) | <0.0001 | <0.001 |
| 0403–0302 | 4 (0.3%) | 8 (0.6%) | 0.5 | (0.152–1.679) | 0.2555 | 0.2643 |
| 0404–0302 | 32 (2.3%) | 16 (1.2%) | 2.05 | (1.12–3.75) | 0.0178 | 0.002 |
| 0405–0302 | 110 (8.0%) | 17 (1.2%) | 7.03 | (4.19–11.78) | <0.0001 | <0.001 |
| 0411–0302 | 3 (0.2%) | 8 (0.6%) | 0.38 | (0.100–1.428) | 0.1359 | 0.1367 |
| 07–0201 | 16 (1.2%) | 38 (2.7%) | 0.42 | (0.23–0.75) | 0.0029 | 0.001 |
| 07–0202 | 55 (4.0%) | 109 (7.9%) | 0.49 | (0.35–0.68) | <0.0001 | <0.001 |
| 08–0301 | 3 (0.2%) | 12 (0.9%) | 0.25 | (0.07–0.89) | 0.021 | 0.067 |
| 08–0402 | 29 (2.1%) | 58 (4.2%) | 0.49 | (0.31–0.78) | 0.0019 | 0.004 |
| 09–0202 | 25 (1.8%) | 6 (0.4%) | 4.27 | (1.75–10.45) | 0.0005 | <0.001 |
| 09–0303 | 17 (1.2%) | 7 (0.5%) | 2.47 | (1.02–5.99) | 0.0376 | 0.234 |
| 10–0501 | 10 (0.7%) | 32 (2.3%) | 0.31 | (0.15–0.63) | 0.0007 | <0.001 |
| 11–0301 | 44 (3.2%) | 92 (6.6%) | 0.47 | (0.32–0.67) | <0.0001 | <0.001 |
| 11–0602 | 0 (0.0%) | 27 (1.9%) | 0.02 | (0.00–0.30) | <0.0001 | <0.001 |
| 12–0301 | 12 (0.9%) | 19 (1.4%) | 0.64 | (0.31–1.31) | 0.218 | 0.457 |
| 13–0301 | 6 (0.4%) | 16 (1.2%) | 0.38 | (0.147–0.965) | 0.0346 | 0.0354 |
| 13–0303 | 3 (0.2%) | 16 (1.2%) | 0.19 | (0.055–0.646) | 0.003 | 0.0041 |
| 13–0602 | 13 (0.9%) | 15 (1.1%) | 0.88 | (0.41–1.85) | 0.727 | 0.582 |
| 13–0603 | 17 (1.2%) | 86 (6.2%) | 0.19 | (0.11–0.32) | <0.0001 | <0.001 |
| 13–0604 | 46 (3.4%) | 38 (2.7%) | 1.23 | (0.79–1.91) | 0.347 | 0.749 |
| 13–0609 | 3 (0.2%) | 12 (0.9%) | 0.25 | (0.071–0.892) | 0.021 | 0.0321 |
| 14–0301 | 1 (0.1%) | 9 (0.6%) | 0.11 | (0.01–0.88) | 0.0119 | — |
| 14–0501 | 3 (0.2%) | 9 (0.6%) | 0.34 | (0.09–1.24) | 0.0862 | — |
| 14–0503 | 7 (0.5%) | 38 (2.7%) | 0.18 | (0.08–0.41) | <0.0001 | <0.001 |
| 15–0601 | 4 (0.3%) | 7 (0.5%) | 0.58 | (0.17–1.97) | 0.375 | — |
| 15–0602 | 17 (1.2%) | 152 (11.0%) | 0.1 | (0.06–0.16) | <0.0001 | <0.001 |
| 16–0301 | 3 (0.2%) | 14 (1.0%) | 0.21 | (0.06–0.75) | 0.008 | 0.005 |
| 16–0502 | 25 (1.8%) | 42 (3.0%) | 0.59 | (0.36–0.98) | 0.0399 | 0.012 |
| Others | 116 (8.5%) | 189 (13.6%) | ||||
| Total | 1355 | 1436 |
T1D = type 1 diabetes mellitus; n = number of individuals; OR = odds ratio; CI = confidence interval; p no-structured = level of significance before strat analysis; p structured = level of significance after strat analysis. Thirty five haplotypes with total number in patients plus controls greater than 10 were included (0.4%). P required for statistical significance after Bonferroni correction for multiple tests <0.0013. Rare alleles were included in others.